Several brokerages have updated their recommendations and price targets on shares of Collegium Pharmaceutical (NASDAQ: COLL) in the last few weeks:
- 9/23/2026 – Collegium Pharmaceutical is now covered by Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $50.00 price target on the stock.
- 9/9/2026 – Collegium Pharmaceutical is now covered by Leerink Partners. They set an “outperform” rating and a $45.00 price target on the stock.
- 9/9/2026 – Collegium Pharmaceutical is now covered by Truist Financial Corporation. They set a “buy” rating and a $49.00 price target on the stock.
- 9/9/2026 – Collegium Pharmaceutical had its price target lowered by Truist Financial Corporation from $58.00 to $49.00. They now have a “buy” rating on the stock.
- 9/9/2026 – Collegium Pharmaceutical is now covered by Leerink Partners. They set an “outperform” rating and a $45.00 price target on the stock.
- 9/4/2026 – Collegium Pharmaceutical was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
- 8/19/2026 – Collegium Pharmaceutical had its price target lowered by Barclays PLC from $56.00 to $48.00. They now have an “overweight” rating on the stock.
- 8/11/2026 – Collegium Pharmaceutical was downgraded by Weiss Ratings from “hold (c)” to “hold (c-)”.
- 8/8/2026 – Collegium Pharmaceutical was downgraded by Wall Street Zen from “buy” to “hold”.
- 8/7/2026 – Collegium Pharmaceutical had its “neutral” rating reaffirmed by Piper Sandler. They now have a $43.00 price target on the stock, down from $45.00.
- 8/6/2026 – Collegium Pharmaceutical had its price target lowered by Needham & Company LLC from $56.00 to $46.00. They now have a “buy” rating on the stock.
- 7/28/2026 – Collegium Pharmaceutical was downgraded by Zacks Research from “strong-buy” to “hold”.
- 7/25/2026 – Collegium Pharmaceutical was downgraded by Wall Street Zen from “strong-buy” to “buy”.
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for patients with central nervous system disorders. The company’s portfolio includes treatments for pain and attention deficit hyperactivity disorder (ADHD), with an emphasis on products that address unmet patient and healthcare-provider needs.
Collegium’s pain portfolio includes Xtampza ER, an extended-release oxycodone product designed with abuse-deterrent properties; Nucynta and Nucynta ER, which contain tapentadol and are used to treat certain types of acute and chronic pain; and Belbuca, a buprenorphine buccal film for the management of chronic pain.
Further Reading
- Five stocks we like better than Collegium Pharmaceutical
- Chips to Bots: Qualcomm’s Agentic AI Breakout
- Ciena Fell 40%—Now One Analyst Sees 50% Upside
- Energy Transfer Taps the AI Power Boom
- Viking’s Obesity Edge May Be Staying Power, Not Weight Loss
Receive News & Ratings for Collegium Pharmaceutical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc and related companies with MarketBeat.com's FREE daily email newsletter.
